When a cat is diagnosed with hypertrophic cardiomyopathy (HCM), the path forward often feels uncertain, but this innovative development in the treatment of feline HCM is changing the game and carving out clearer treatment paths. In this episode of the Partner Podcast, Dr. Ashlie Saffire explores how a new targeted treatment, Felycin-CA1, may transform not only how veterinarians manage this common feline heart disease but also how we think about screening for subclinical HCM in practice.Sponsored by PRN PharmacalResource:Felycin.comContact us:[email protected] to find us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/X: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostTaylor Argo- Producer, Sound Editing, & Project Manager, Brief Studio

Ver todos los episodios